For People with Covid-19, or It may help prevent people who have been exposed or who are at high risk of exposure to someone who is infected with SARS-CoV-2 from getting it.
The results from the Phase 3 clinical trial show that the treatment maintains the 81.4% effectiveness that was reported one month after being administered.
The New York-based drugmaker says the antibody cocktail, called REGEN-COV, could provide long-lasting immunity to people who do not respond to COVID-19 vaccines, including people who are immunocompromised.
REGEN-COV, which combines the monoclonal antibodies casirivimab with imdevimab, is administered through IV.
The clinical trial was conducted jointly with the National Institute of Allergy and Infectious Diseases.
Monoclonal antibodies for COVID-19 may block the virus that causes COVID-19 from attaching to human cells, making it more difficult for the virus to reproduce and cause harm. Monoclonal antibodies may also neutralize a virus.
We have been in service of the community for over ten years, standing strong by our patient-centered philosophies combined with our exceptionally high moral values, and will continue to do so into the future.
Through our years of experience and humble approach to overall patient satisfaction, we have stood by our belief that good physical health leads to good mental health and that is what we plan to achieve through our range of services: happiness through good health.
Due to the scourge of the COVID-19 pandemic, the CDC recommends that travelers within or